PLUS1
18.75
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Dermira Inc | DERM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 18.75 | 20:00:00 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 18.75 | 0.00 | 0.00 | 0.00 | 18.75 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 18.66 | 18.74 | 0.08 | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 18.75 | USD |
Dermira Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.03B | 54.70M | 49.69M | $ 42.34M | $ - | -5.27 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Dermira News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/09/2020 | 16:28 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 3/02/2020 | 07:47 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under.. |
| 2/25/2020 | 06:00 | Edgar (US Regulatory) | Notice of Effectiveness (effect) |
| 2/24/2020 | 10:05 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 2/20/2020 | 16:01 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/20/2020 | 10:12 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) |
| 2/20/2020 | 09:55 | Edgar (US Regulatory) | Post-effective Amendment to an Automatic Shelf Registration.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DERM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 6 Months | 18.75 | 18.77 | 18.60 | 18.74 | 793,479 | 0.00 | 0.0% |
| 1 Year | 8.40 | 25.99 | 5.25 | 13.58 | 1,673,437 | 10.35 | 123.21% |
| 3 Years | 23.31 | 31.42 | 5.25 | 12.96 | 1,096,875 | -4.56 | -19.56% |
| 5 Years | 25.12 | 38.75 | 5.25 | 15.58 | 726,544 | -6.37 | -25.36% |
Dermira Description
| Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. |
